Skip to content
Disclosery

Saturn V Capital Management LP

Follow

13F filer, CIK 1964437, AUSTIN, TX

Saturn V Capital Management LP reported $198,158,284 across 21 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-15. Its ten largest share positions make up 77.38% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001964437-25-000005

Period
2025-03-31
Reported value
$198M
Holdings
21
Top 10 weight
77.38%
New
1
Sold out
4

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CNTAnew+448,692$6.45M
AMLXadded+1,537,363$5.44M
MERUS N Vadded+88,574$3.73M
XENEadded+91,241$3.06M
OCULadded+406,735$2.98M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CYTKexited-348,364-$16.4M
CARGO THERAPEUTICS INC COMexited-1,007,677-$14.5M
IRWDexited-814,533-$3.61M
ARGXreduced-5,892-$3.49M
KALVreduced-301,429-$3.48M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0001964437-25-000005, largest first. % of portfolio is the value over $198,158,284, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 200,285 shares; 2024Q4: 198,977 shares; 2025Q1: 199,264 shares 199,264$31.1M15.67%+287Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 511,041 shares; 2024Q4: 509,406 shares; 2025Q1: 518,177 shares 518,177$25.7M12.98%+8,771Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 520,119 shares; 2024Q4: 593,262 shares; 2025Q1: 577,696 shares 577,696$14.1M7.14%-15,566Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 322,470 shares; 2025Q1: 413,711 shares 413,711$13.9M7%+91,241Timeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 131,240 shares; 2024Q4: 234,637 shares; 2025Q1: 323,211 shares 323,211$13.6M6.87%+88,574
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 298,974 shares; 2024Q4: 346,111 shares; 2025Q1: 343,849 shares 343,849$13.4M6.78%-2,262Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 501,978 shares; 2024Q4: 988,528 shares; 2025Q1: 1,041,280 shares 1,041,280$12.8M6.46%+52,752Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 946,335 shares; 2024Q4: 1,063,783 shares; 2025Q1: 1,093,677 shares 1,093,677$11.1M5.58%+29,894Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,712,899 shares; 2024Q4: 1,498,425 shares; 2025Q1: 1,480,020 shares 1,480,020$8.87M4.47%-18,405Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 204,987 shares; 2024Q4: 204,285 shares; 2025Q1: 232,295 shares 232,295$8.77M4.43%+28,010Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 889,073 shares; 2025Q1: 2,426,436 shares 2,426,436$8.59M4.33%+1,537,363Timeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 22,111 shares; 2024Q4: 19,754 shares; 2025Q1: 13,862 shares 13,862$8.2M4.14%-5,892Timeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 448,692 shares 448,692$6.45M3.26%newTimeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 191,456 shares; 2025Q1: 598,191 shares 598,191$4.38M2.21%+406,735Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 77,297 shares; 2024Q4: 573,022 shares; 2025Q1: 560,979 shares 560,979$3.92M1.98%-12,043Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 648,019 shares; 2024Q4: 653,071 shares; 2025Q1: 552,926 shares 552,926$3.46M1.74%-100,145Timeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 556,489 shares; 2024Q4: 556,489 shares; 2025Q1: 255,060 shares 255,060$2.94M1.49%-301,429Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 100,000 shares; 2025Q1: 116,353 shares 116,353$2.38M1.2%+16,353Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 481,127 shares; 2024Q4: 395,024 shares; 2025Q1: 732,463 shares 732,463$2.07M1.04%+337,439Timeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 109,567 shares; 2024Q4: 59,125 shares; 2025Q1: 59,017 shares 59,017$1.98M1%-108Timeline
INOZYME PHARMA INCINOZYME PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,368,810 shares; 2024Q4: 1,374,582 shares; 2025Q1: 499,254 shares 499,254$454K0.23%-875,328

Sold out in Q1 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CYTKCYTOKINETICS INC348,364$16.4Mshares
CARGO THERAPEUTICS INC COMCARGO THERAPEUTICS INC COM1,007,677$14.5Mshares
IRWDIRONWOOD PHARMACEUTICALS INC814,533$3.61Mshares
MBXMBX BIOSCIENCES INC18,000$332Kshares

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001964437-25-000005 base2025-05-15acceptance time not in the bulk data set